Blood levels of tumor necrosis factor alpha (TNF-a), an inflammatory molecule, and phosphorylated alpha-synuclein, a Parkinson’s disease biomarker, could be used to distinguish Parkinson’s patients with or without fatigue. Those findings from a recent study suggest the two markers may be  “promising biomarkers in discriminating PD [Parkinson’s disease] with…

Inflammatory biomarkers in the cerebrospinal fluid (CSF) of Parkinson’s disease patients with and without mutations in the GBA gene are at similar levels, and across all patients, higher levels of these markers associate with poorer cognition over time, a study found. TNF-alpha, a pro-inflammatory molecule, showed particular potential as a predictive…

People with Parkinson’s disease and rapid eye movement (REM) sleep behavior disorder — marked by acting out dreams, sometimes violently — showed no significant differences in their levels of tumor necrosis factor (TNF)-alpha, an inflammatory protein, and orexin, a protective protein, relative to patients without this sleep disorder or people…

Infusions with plasma from young adults is safe and well tolerated in people with moderate Parkinson’s disease, and appear to result in rapid and sustained improvements in phonetic fluency and self-esteem, according to findings from a small Phase 1 trial. These results not only demonstrate the safety and benefits…

People with Parkinson’s disease associated with mutations in the GBA gene have elevated levels of inflammatory signaling molecules in their blood, a new study suggests. The study, “Plasma Cytokines Profile in Patients with Parkinson’s Disease Associated with Mutations in GBA Gene,” was published in the Bulletin…

A blood test may be able to predict early cognitive decline in people with Parkinson’s disease by measuring the length of chromosomal telomeres (the “tips” of chromosomes) in immune cells and the presence of inflammatory markers, a study shows. The study, “…